Literature DB >> 34704211

Study Characteristics and Risk of Bias of Clinical Trials Supporting FDA Approval of Cardiovascular Drugs, 2006-2020.

Meijun Shu1, Siliang Chen1, Jiarui Li2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2021        PMID： 34704211      PMCID： PMC9411468          DOI： 10.1007/s11606-021-07142-4

Source DB:  PubMed          Journal:  J Gen Intern Med        ISSN： 0884-8734            Impact factor:   6.473


× No keyword cloud information.
  4 in total

Review 1.  Are missing outcome data adequately handled? A review of published randomized controlled trials in major medical journals.

Authors:  Angela M Wood; Ian R White; Simon G Thompson
Journal:  Clin Trials       Date:  2004       Impact factor: 2.486

2.  RoB 2: a revised tool for assessing risk of bias in randomised trials.

Authors:  Jonathan A C Sterne; Jelena Savović; Matthew J Page; Roy G Elbers; Natalie S Blencowe; Isabelle Boutron; Christopher J Cates; Hung-Yuan Cheng; Mark S Corbett; Sandra M Eldridge; Jonathan R Emberson; Miguel A Hernán; Sally Hopewell; Asbjørn Hróbjartsson; Daniela R Junqueira; Peter Jüni; Jamie J Kirkham; Toby Lasserson; Tianjing Li; Alexandra McAleenan; Barnaby C Reeves; Sasha Shepperd; Ian Shrier; Lesley A Stewart; Kate Tilling; Ian R White; Penny F Whiting; Julian P T Higgins
Journal:  BMJ       Date:  2019-08-28

3.  Allocation concealment in randomised controlled trials: are we getting better?

Authors:  Laura Clark; Caroline Fairhurst; David J Torgerson
Journal:  BMJ       Date:  2016-11-17

Review 4.  Empirical Evidence of Study Design Biases in Randomized Trials: Systematic Review of Meta-Epidemiological Studies.

Authors:  Matthew J Page; Julian P T Higgins; Gemma Clayton; Jonathan A C Sterne; Asbjørn Hróbjartsson; Jelena Savović
Journal:  PLoS One       Date:  2016-07-11       Impact factor: 3.240
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.